Penn reports strong demand for its pharmaceutical services
This article was originally published in Scrip
The Wales-based firm, Penn Pharmaceutical Services, has reported full-year revenues of £23.3 million, a 34% increase on those a year ago. The company notes that the strong demand for its formulation, development and custom manufacturing services has led to it appointing 43 new employees over the past year, and the opening of new high potency drug and warehousing facilities. Penn is also growing its presence on the east and west coasts of the US, and in Japan.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.